# Amgen

OpenAI Steps into the Lab: GPT-Rosalind and the High-Stakes Battle for AI-Driven Cures

OpenAI has launched GPT-Rosalind, a specialized AI model for drug discovery, marking a direct challenge to Google's dominance in the life sciences sector. Partnering with industry leaders like Moderna and Amgen, OpenAI aims to leverage its generative technology to accelerate the translation of biological data into clinical medical applications.